middle.news
Dimerix Advances Kidney Disease Treatment with US Licensing Deal for DMX-200
3:38am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Dimerix Advances Kidney Disease Treatment with US Licensing Deal for DMX-200
3:38am on Monday 2nd of June, 2025 AEST
Key Points
US licensing transaction secured for DMX-200, a Phase 3 clinical asset
DMX-200 targets Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease
Orphan Drug Designation granted in US and Europe for DMX-200
Phase 3 clinical trial progress to be discussed in upcoming investor webinar
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE